Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
ANVS Total Current Assets
All assets expected to be converted to cash or used up within one year.
Annovis Bio, Inc.NYSE: ANVS
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets falls 39.2% from a year ago
Total current assets stood at $16.24M at the end of Q1 FY2026, down 39.2% from a year earlier and down 22.9% from the prior quarter. Over 3 fiscal years it compounded at -16.4% a year.
Context
- Total current assets amounted to 100.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total current assets keeps falling in the next quarterly balance sheet after a -39.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 21.08M USD
- Year-over-year change
- +51.4%
- 4-year CAGR
- -17.7%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.08M | +51.4% |
| FY2024 | 2024-12-31 | 13.93M | +36.4% |
| FY2023 | 2023-12-31 | 10.21M | -71.7% |
| FY2022 | 2022-12-31 | 36.02M | -21.7% |
| FY2021 | 2021-12-31 | 46M | — |
Total Current Assets vs competitors
How ANVS compares with its peers on the latest reported figures
- ANVS's Mar 2026 total current assets of $16.24M is the 4th highest of the 6 companies compared; the peer median is $22.89M.
- Its year-over-year change of -39.2% is the 4th highest of 6, against a peer median of -38.2%.
- Total current assets amounts to 100.0% of total assets for ANVS, versus a peer median of 92.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $37.74M | -38.2% | -23.6% | 94.0% | |
| Mar 2026 | $35.32M | +197.7% | -6.3% | 100.0% | |
| Mar 2026 | $22.89M | -46.1% | -28.2% | 92.8% | |
| Mar 2026 | $16.24M | -39.2% | -16.4% | 100.0% | |
| Mar 2026 | $12.56M | +43.2% | +2.4% | 65.6% | |
| Dec 2025 | $12.32M | -40.1% | -28.4% | 11.5% | |
| Peer median (excluding ANVS) | $22.89M | -38.2% | -23.6% | 92.8% | |
Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Annovis Bio, Inc.
NYSE:ANVS
Intrinsic Alpha fair value
Locked
Current Price
$1.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.